Recent advances in breast cancer cell line research

Abstract

Breast cancer, a formidable global health challenge, needs continuous translational research to understand the complexity of mechanisms and improve therapeutic and diagnostic strategies. Breast cancer cell lines are of paramount importance as they significantly contribute to the initial stage of research to understand cancer biology. This review provides insights into targeted therapies and immunotherapies that have emerged using in vitro models and microbiome analysis. It focuses on therapeutic development using cell lines and the limitations of tumor heterogeneity and microenvironment. We explore the evolving landscape of breast cancer cell lines from two‐dimensional (2‐D) cultures to patient‐derived xenograft (PDX) models advancing both fundamental and translational research. Patient‐derived xenografts, cell line‐derived xenografts (CDX), three‐dimensional (3‐D) cultures, organoids, and circulating tumor cells (CTC) models provide promising alternatives that capture the intricacies of the tumor microenvironment. This review bridges the gap between traditional cell lines and newer developments exploring the therapeutic and diagnostic advancements and needs for cell lines to expedite the progress in breast cancer research and treatment.

Effects of Garlic on Breast Tumor Cells with a Triple Negative Phenotype: Peculiar Subtype-Dependent Down-Modulation of Akt Signaling

“…We revealed that in HBCX-17 and T174 cells, belonging to the mesenchymal subtype (M), GE has a strong toxic effect, without significantly affecting the cell cycle and invasive potential. Regarding variance, in the mesenchymal (M) HBCX-9, and in HBCX-39, classified as basal-like 1 (BL1) by Coussy et al [44], a modest toxic concentration of GE blocked the cell cycle, induced apoptosis, and reduced invasion capability, as in mesenchymal MDA-MB-231 cells [45].…”